GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) announced two AI-assisted capabilities for its Vscan Air handheld ultrasound system: Lung Guidance and AutoAS. Both are FDA 510(k) cleared and CE marked and available for purchase through Vscan Air Innovation Packages in the United States and select countries. They are available only on Vscan Air SL.
Lung Guidance supports lung image acquisition. In descriptive validation testing, non-expert users acquired diagnostic-quality exams with 95.2 percent success, compared with 96.8 percent for experts. AutoAS estimates whether cardiac images suggest moderate-to-severe aortic stenosis, a narrowing of the aortic valve; it is a diagnostic aid, not a standalone diagnostic tool. GE HealthCare expects existing customers with a valid Innovation Package subscription or license to receive the updates by the end of November 2026.
GE HealthCare (Nasdaq: GEHC) introduced Allia Celeo, a ceiling-mounted image-guidance system for cardiology and interventional radiology, at TCT 2026.
The system is CE marked, but its U.S. FDA 510(k) clearance is pending and it is not available for sale in the United States. Availability may also vary by region. GE HealthCare designed the system with a wide-bore gantry, an on-screen digital twin for positioning, and AI-enabled imaging intended to balance image quality and radiation dose. It is designed for compatibility with existing clinical applications and OnWatch Predict, which combines remote monitoring with predictive analytics to anticipate unplanned downtime.
Allia Celeo follows the floor-mounted Allia Moveo, commercially launched earlier this year, as the second new Allia system introduced in less than a year.
GE HealthCare (Nasdaq: GEHC) reported third-quarter 2026 revenue growth of 7.2% and raised its full-year outlook following higher earnings. Revenue reached $5.513 billion, with organic growth, excluding acquisitions, dispositions and currency effects, of 6.2%. Net income attributable to GE HealthCare rose to $615 million from $446 million, and diluted earnings per share increased to $1.36 from $0.98.
Operating cash flow was $907 million, up $314 million, including a $55 million tariff refund. All three segments grew revenue and expanded operating margins. The company now expects full-year adjusted earnings per share of $4.95–$5.05, versus $4.80–$5.00 previously, and free cash flow above $1.6 billion. The quarterly dividend increased 14% to $0.04 per share. GE HealthCare also plans to acquire SOFIE Biosciences for $945 million in cash, with closing expected in the first half of 2027, subject to regulatory approvals.
GE HealthCare (GEHC) announced five global clinical collaborations to evaluate StarGuide GX, its digital nuclear medicine imaging system. The program spans three continents and includes Hadassah Medical Center, Mayo Clinic, Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse, Peking University First Hospital and Rambam Health Care Campus. Evaluations will cover image quality, quantitative performance, dynamic imaging and workflow; GE HealthCare expects the feedback to inform the platform’s future development.
The collaborations build on work with University Hospital Essen, which opened a nuclear medicine center featuring the first StarGuide GX installation in June 2026. These institutions have scanned more than 1,000 patients to date. StarGuide GX received CE Mark in November 2025 and is available in select EU member states. U.S. FDA 510(k) clearance remains pending, and the system is not available for sale in the United States.
GE HealthCare (GEHC) announced LOGIQ Focus, a general imaging ultrasound system with regulatory clearance and tools intended to support everyday examinations. The system is 510(k) cleared and CE Marked, with availability in other markets where regulatory approval has been granted. GE HealthCare expects several new products, including LOGIQ Focus, to contribute 1 to 2 percent of company revenue growth; that expectation is not specific to LOGIQ Focus alone.
In a third-party study of right upper quadrant abdominal examinations, 90 percent of physicians rated overall image quality as excellent, defined as at least 4 on a 5-point scale. A July 2026 head-to-head comparison found the system 26 percent faster than the predicate device for abdominal scans. Its tools include automated exam settings and measurements, alongside virtual collaboration that is not for diagnostic use.
GE HealthCare (Nasdaq: GEHC) announced published University of Michigan research linking End-tidal Control software use with reduced anesthesia gas consumption.
The retrospective observational study in Anesthesia & Analgesia Practice analyzed 12,818 adult general anesthesia cases at University of Michigan Health–Ann Arbor locations between April 1, 2023 and September 30, 2024. The software was used in 6,755 cases (52.7%). Its use was associated with a 62.3% reduction in median fresh gas flow during anesthesia maintenance and a 39.3% reduction in sevoflurane consumption. Variation in use was significantly driven by the in-room anesthesia clinician. GE HealthCare partially funded data extraction and analysis.
GE HealthCare (GEHC) has achieved CE Mark for its MINItrace Magni cyclotron and added Copper-64 production support to PETtrace.
MINItrace Magni is designed for local production of radioisotopes used in positron emission tomography (PET), a medical imaging technique. It combines a compact, self-shielded design with automated operation. The addition of Copper-64 expands the PETtrace Solid Target Platform beyond Gallium-68 and Zirconium-89. Copper-64 supports imaging research and is being studied alongside investigational Copper-67 agents as a potential diagnostic and therapeutic pair; this is not an established therapeutic application.
GE HealthCare (GEHC) will announce its third quarter 2026 financial results before the market opens on October 28, 2026.
Management will host a conference call and live webcast that day at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time. The earnings release, accompanying financial information and webcast replay will be available on the company’s Investor Relations website.
GE HealthCare (Nasdaq: GEHC) signed a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. Closing is expected in the first half of 2027, subject to regulatory approvals and other closing conditions. SOFIE will join the Pharmaceutical Diagnostics segment.
The acquisition adds a U.S. manufacturing network of 15 sites operating 21 cyclotrons and a development and manufacturing site focused on paired diagnostic and therapeutic approaches. It also provides U.S. rights to FAPI-74, a Phase III PET radiotracer, an imaging agent; GE HealthCare already holds rights outside the U.S. GE HealthCare expects SOFIE to grow in the low double digits under its ownership and estimates the transaction will improve revenue growth, adjusted earnings before interest and taxes margin, and adjusted earnings per share in the first full year of ownership.
GE HealthCare (GEHC)/b) declared a cash dividend of $0.04 per share of common stock for the third quarter of 2026. This represents a 14% increase from the previous quarter's dividend. The dividend will be paid on November 13, 2026, to shareholders who are on record as of October 23, 2026.